LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys - Wikidata - wikimedia - TriplyDB

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

http://www.wikidata.org/entity/Q34792753

about

Nuclear receptors and AMPK: can exercise mimetics cure diabetes?Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy Inventing new medicines: The FGF21 story Action and therapeutic potential of oxyntomodulin Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders.Serum FGF21 levels are associated with brown adipose tissue activity in humans.Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues.Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets.Reduced adiposity attenuates FGF21 mediated metabolic improvements in the Siberian hamster.Autophagy and non-alcoholic fatty liver disease.Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice.FGF21 does not require interscapular brown adipose tissue and improves liver metabolic profile in animal models of obesity and insulin-resistance.Glucagon-to-insulin ratio is pivotal for splanchnic regulation of FGF-21 in humans Circulating FGF21 proteolytic processing mediated by fibroblast activation protein.PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates.FGF21 is not required for glucose homeostasis, ketosis or tumour suppression associated with ketogenic diets in mice.Fibroblast growth factor 21: a promising therapeutic target in obesity-related diseases.Latest approaches for the treatment of obesity.Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.FGF21 improves glucose homeostasis in an obese diabetes-prone mouse model independent of body fat changes.Can aging be 'drugged'?Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus.Targeting adipose tissue in the treatment of obesity-associated diabetes.Fibroblast growth factor 21 night watch: advances and uncertainties in the field.Nutrition, metabolism, and targeting aging in nonhuman primates.The Potential Role of Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension.Fibroblast Growth Factor 21 Mimetics for Treating Atherosclerosis.Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice.FGF21 mimetic antibody stimulates UCP1-independent brown fat thermogenesis via FGFR1/βKlotho complex in non-adipocytes.Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates.Highly selective and sensitive measurement of active forms of FGF21 using novel immunocapture enrichment with LC-MS/MS.LY2405319, an analog of fibroblast growth factor 21 ameliorates α-smooth muscle actin production through inhibition of the succinate-G-protein couple receptor 91 (GPR91) pathway in mice.Hepatic FGF21 production is increased in late pregnancy in the mouse.Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing.Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity.FGF21 gene therapy as treatment for obesity and insulin resistance

P2860

Q26750875-74CD2FE8-304D-408F-AFB0-0EE94A087EE8 Q26781556-3369121C-E30A-4459-9F82-3CB4AEF9EBC0 Q26823319-4399AB31-7E37-4072-985E-9D0324AEA594 Q27025870-86676E92-DAD8-48B5-919A-2858879DFE2D Q27686803-28F03B19-3DEE-430C-9E39-D1075A6C9772 Q30374773-1A84F5D0-A1A2-4609-B22B-1ECFC818C713 Q30597265-287AF504-9352-426A-9021-D9CB81179614 Q33685319-1EA9DA05-2F97-4476-8BF7-C3CA5D910CB7 Q33808884-B714DBD8-4DD8-406A-A502-00784D2B7E14 Q33835303-876005B0-C3BA-4842-8A9F-F5E8B6C5C253 Q34247340-0FE0AD6E-7E27-486C-A2C3-2852971E3F49 Q35581474-AADC8B8C-41CB-4C32-9010-56048D947471 Q35648897-6A01F3B3-8A0C-4878-B8FA-5ABC63BE2EF3 Q35830589-ED32E858-2721-4A13-A091-D95FE709A4B8 Q35929501-AFAB8D82-4F4C-48B2-8CBC-C427DBE38401 Q36611366-867888E7-DFB3-4844-8128-AC6EB3CD452B Q37112476-8C13C3BE-2783-4826-B86B-1C22866071CB Q37485018-1D9B1BF2-E5F4-4D84-9574-3D66E709E1C4 Q38201778-8EE4CA95-D4A8-4053-AA44-B3EE9127BF5F Q38475978-B89EF31C-3A07-4686-99F8-A5EB34F6B965 Q38633258-5E5A5B23-F25D-4CE8-AD70-391AC5328F0D Q38645276-5A0AF570-476F-42DA-90F7-230A78C1D29B Q38662550-DFE386E6-8E94-49E3-A412-E5C714456970 Q38794405-2A65B536-1ABA-4921-905A-B302A742C540 Q38852204-C36BE022-F0F1-4134-8621-28EEBCBB8816 Q39017842-1F130AA3-ADE5-4EC8-89F6-4621DB939741 Q39144678-F379E70A-9E9D-46A8-A0D1-D1D55D9B40BB Q39197925-7905CF30-5168-4A39-968E-BACBC71DE1CB Q39325845-E6706B47-A059-4FE5-A0A3-535929FE0550 Q42051129-B5D73C77-F116-4E30-93F8-1651FFAFC8FE Q47096943-88AF0EE6-CE3C-41C2-96CE-41D6FB2C84FF Q47209022-81AF238F-30E1-4223-8037-48B7B180E67B Q49846751-EEC46241-FDC8-493B-AE13-BC33BC078614 Q50000450-20DD6A5B-618C-4F10-9032-AC1CE2F0A88D Q51136093-93E0A437-737D-4C97-B301-A4D8508A43A5 Q51730495-71DB7062-889B-4D20-A356-FF3D74A9E090 Q55490578-EF8E40CB-A78D-4ED7-9012-C92B0DD41D9F Q57688659-92657D19-7EF9-4617-9EA6-F0648D9753E3

P2860

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

http://www.wikidata.org/entity/Q34792753

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

@ast

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

@en

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

@nl

type

label

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

@ast

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

@en

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

@nl

prefLabel

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

@ast

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

@en

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

@nl

P1433

Q34792753-C74FCEC7-E3BE-48BF-8BB6-B2FE946B25B7

P1476

Q34792753-3BAEEEB5-2176-4580-B77B-C2F80C8874BC

P2093

Q34792753-2282D108-F4A7-4C22-B292-764A0BCB97B8

Q34792753-4CE9FD20-07A7-4963-B2EC-CD35D3DF9592

Q34792753-77BDA9EF-030B-41EF-AB37-613EF166CFDA

Q34792753-80FC47DA-95F8-4618-A129-1FA4C0815DF8

Q34792753-B1D79EEC-C41B-49BC-96D1-E07DFAB082F4

Q34792753-C3B7ABF1-59EF-423B-972B-06B83EEB3394

Q34792753-D6A59258-957A-465A-AEDC-98C087ABF8DD

Q34792753-ED3E8147-C385-4086-8517-CBE5F34761EE

Q34792753-EF650A4E-CD18-41A9-9505-E42A3A098216

Q34792753-FE5808C3-2A40-45FE-BE00-B413C5C637C8

P2860

Q34792753-15F63D5A-D64C-489B-BFD2-BCB58AEAAA68

Q34792753-1EABDF16-2DEB-4EAB-9FD1-4B66C2AE9617

Q34792753-2823B4AE-B59F-4CE6-9C74-C50516CEED16

Q34792753-34E22342-9285-458F-A0A8-5A7A73A223A3

Q34792753-3F836E89-3B1B-413A-9F37-2A265D09FC15

Q34792753-494CA54D-E648-4496-B25A-97804D1D387E

Q34792753-4F051606-5ACB-449D-9B34-509C42C3C929

Q34792753-60F98A25-C7F5-4DF1-AE8D-C6415C6A5E96

Q34792753-65442343-A0B5-46A3-AFDC-9949D204E33A

Q34792753-6798BB79-2BEC-4326-BEF1-E3522E5A1E58

P304

Q34792753-6E15BB9D-1969-4FDD-B7B1-D490C45E7941

P31

Q34792753-EAB3685C-1586-4F30-A3CD-1167762C118C

P356

Q34792753-25437980-2583-4D94-B7D9-70B861B58B10

P407

Q34792753-6ACC1494-5E9F-44DD-B068-8B62B5D1B363

P433

Q34792753-2B4E518C-45EB-44B5-9ED3-56041D5F37DE

P478

Q34792753-17D1257D-5D7A-4CCE-9188-1D59F4280FAD

P577

Q34792753-E956133F-D8B5-4B69-9E71-EAD0E391FF50

P5875

Q34792753-BE66D17E-50A3-4A2F-8894-4D7F96AA7D46

P698

Q34792753-128F929A-4B95-4A20-AA73-E1628AE1DE1B

P932

Q34792753-47372CA9-73F9-4849-87EF-AAA2CB70ABC7

P356

JOURNAL.PONE.0065763

P1433

P1476

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

@en

P2093

Alexei Kharitonenkov

http://www.w3.org/2001/XMLSchema#string

Andrew C Adams

http://www.w3.org/2001/XMLSchema#string

Armando R Irizarry

http://www.w3.org/2001/XMLSchema#string

Barbara C Hansen

http://www.w3.org/2001/XMLSchema#string

Carolyn A Halstead

http://www.w3.org/2001/XMLSchema#string

Holly W Smith

http://www.w3.org/2001/XMLSchema#string

Jennifer A Martin

http://www.w3.org/2001/XMLSchema#string

Sharon R Myers

http://www.w3.org/2001/XMLSchema#string

Victor J Wroblewski

http://www.w3.org/2001/XMLSchema#string

Vincent L Reynolds

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a novel FGF, FGF-21, preferentially expressed in the liver

FGF-21 as a novel metabolic regulator.

Fibroblast growth factor 21: from pharmacology to physiology

FGF21 promotes metabolic homeostasis via white adipose and leptin in mice

FGF21 requires βklotho to act in vivo

Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319

Fundamentals of FGF19 & FGF21 action in vitro and in vivo

The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.

Fibroblast growth factor 21 corrects obesity in mice.

βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism

P304

e65763

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0065763

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

245028068

http://www.w3.org/2001/XMLSchema#string

P698

23823755

http://www.w3.org/2001/XMLSchema#string

P932

3688819

http://www.w3.org/2001/XMLSchema#string